Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
COMy 2023
Wonderful speaking with @aditishasMD (@MontefioreNYC) at #ASH23 where early results reveal promising safety, PK, and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed/refractory #Lymphoma
@ASH_hematology #Lymsm
It was lovely speaking with @beatalleukemia (@OSUCCC_James) at #ASH23 who spoke about advances in the treatment paradigm of myeloid malignancies, including novel investigational combinations being explored for higher-risk #MDS
#ASH23 @ASH_hematology #MyelodysplasticSyndromes
It was great catching up with @mkonople (@EinsteinMed) on the Nanobody® T Cell Engager, a dual-targeting CD33/CD123 therapy that attacks both leukemia blasts and stem/progenitor cells in relapsed #AML
#ASH23 @ASH_hematology #Leukemia #Leusm
Promising strides in #leukemia treatment from Jeffrey Lancet (@MoffittNews)!
Early findings from COVALENT-101 on BMF-219, a covalent menin inhibitor, show encouraging results in patients with relapsed/refractory #AcuteLeukemia
#ASH23 @ASH_hematology #Leusm
#ASH23 Looking forward to learning together, teaching, raising awareness for patients with #RareDiseases collaborating, new ideas 💡 & exhilarating debates & discussions @ASH_hematology meeting !! @sanamloghavi @acweyand @tmprowell @mtmdphd @mpdrc |#MPNSM #BPDCN #leusm
COMy 2023
Wonderful speaking with @aditishasMD (@MontefioreNYC) at #ASH23 where early results reveal promising safety, PK, and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed/refractory #Lymphoma
@ASH_hematology #Lymsm
It was lovely speaking with @beatalleukemia (@OSUCCC_James) at #ASH23 who spoke about advances in the treatment paradigm of myeloid malignancies, including novel investigational combinations being explored for higher-risk #MDS
#ASH23 @ASH_hematology #MyelodysplasticSyndromes
It was great catching up with @mkonople (@EinsteinMed) on the Nanobody® T Cell Engager, a dual-targeting CD33/CD123 therapy that attacks both leukemia blasts and stem/progenitor cells in relapsed #AML
#ASH23 @ASH_hematology #Leukemia #Leusm
Promising strides in #leukemia treatment from Jeffrey Lancet (@MoffittNews)!
Early findings from COVALENT-101 on BMF-219, a covalent menin inhibitor, show encouraging results in patients with relapsed/refractory #AcuteLeukemia
#ASH23 @ASH_hematology #Leusm
#ASH23 Looking forward to learning together, teaching, raising awareness for patients with #RareDiseases collaborating, new ideas 💡 & exhilarating debates & discussions @ASH_hematology meeting !! @sanamloghavi @acweyand @tmprowell @mtmdphd @mpdrc |#MPNSM #BPDCN #leusm
